EP0909323B1
(en)
|
1996-01-04 |
2007-02-28 |
Novartis Vaccines and Diagnostics, Inc. |
Helicobacter pylori bacterioferritin
|
US5858389A
(en)
*
|
1996-08-28 |
1999-01-12 |
Shaker H. Elsherbini |
Squalene is an antiviral compound for treating hepatitis C virus carriers
|
AT405939B
(de)
*
|
1997-02-24 |
1999-12-27 |
Immuno Ag |
Verfahren zur inaktivierung von lipidumhüllten viren
|
US6406705B1
(en)
*
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
GB9712347D0
(en)
*
|
1997-06-14 |
1997-08-13 |
Smithkline Beecham Biolog |
Vaccine
|
GB9718901D0
(en)
*
|
1997-09-05 |
1997-11-12 |
Smithkline Beecham Biolog |
Vaccine
|
GB9727262D0
(en)
*
|
1997-12-24 |
1998-02-25 |
Smithkline Beecham Biolog |
Vaccine
|
ATE357526T1
(de)
*
|
1998-08-21 |
2007-04-15 |
Us Gov Health & Human Serv |
Modifizierte hcv peptid-impfstoffe
|
EP2266604A3
(en)
|
1998-10-16 |
2011-05-11 |
GlaxoSmithKline Biologicals S.A. |
Adjuvant systems and vaccines
|
GB9908885D0
(en)
*
|
1999-04-19 |
1999-06-16 |
Smithkline Beecham Biolog |
Vccine
|
WO2001037869A1
(en)
*
|
1999-11-19 |
2001-05-31 |
Csl Limited |
Vaccine compositions
|
CA2881568C
(en)
|
2000-10-27 |
2019-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from streptococcus groups a & b
|
AU2002227365A1
(en)
|
2000-12-07 |
2002-06-18 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
CA2476626A1
(en)
|
2002-02-20 |
2003-08-28 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
EP1481006A2
(en)
*
|
2002-03-04 |
2004-12-01 |
Zagyansky, Yuly |
Universal antimicrobial treatment
|
US8518694B2
(en)
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
SI2351579T1
(sl)
|
2002-10-11 |
2017-05-31 |
Glaxosmithkline Biologicals Sa |
Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
CN101926988B
(zh)
|
2003-01-30 |
2014-06-04 |
诺华疫苗和诊断有限公司 |
抗多种脑膜炎球菌血清组的可注射性疫苗
|
WO2004087153A2
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US9107831B2
(en)
|
2003-06-02 |
2015-08-18 |
Novartis Vaccines And Diagonstics, Inc. |
Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
ATE506963T1
(de)
|
2003-10-02 |
2011-05-15 |
Novartis Vaccines & Diagnostic |
Kombinationsimpfstoffe gegen meningitis
|
WO2005107797A1
(en)
|
2004-03-09 |
2005-11-17 |
Chiron Corporation |
Influenza virus vaccines
|
PL1740217T3
(pl)
|
2004-04-30 |
2012-03-30 |
Novartis Ag |
Szczepienie koniugatem meningokokowym
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
CA2567446C
(en)
|
2004-05-21 |
2018-01-02 |
Chiron Corporation |
Alphavirus vectors for respiratory pathogen vaccines
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
EP1765313A2
(en)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
PT2682126T
(pt)
|
2005-01-27 |
2017-02-28 |
Children`S Hospital & Res Center At Oakland |
Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
HUE030881T2
(en)
|
2005-02-18 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Meningitis / sepsis-associated escherichia coli proteins and nucleic acids
|
JP2009511636A
(ja)
|
2005-10-18 |
2009-03-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
|
EP2360175B1
(en)
|
2005-11-22 |
2014-07-16 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus and Sapovirus virus-like particles (VLPs)
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
ES2376492T3
(es)
|
2006-03-23 |
2012-03-14 |
Novartis Ag |
Compuestos de imidazoquinoxalina como inmunomoduladores.
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
BRPI0816689B1
(pt)
|
2007-09-12 |
2021-08-24 |
Novartis Ag |
Composição de vacina, kit e método para a confecção de uma composição de vacina para a prevenção ou tratamento de infecção por streptococcus pyogenes
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ601543A
(en)
|
2007-12-21 |
2013-03-28 |
Novartis Ag |
Mutant forms of streptolysin o
|
EP2886551A3
(en)
|
2008-02-21 |
2015-09-23 |
Novartis AG |
Meningococcal fhbp polypeptides
|
US9511131B2
(en)
|
2008-03-10 |
2016-12-06 |
Children's Hospital & Research Center Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
NZ592977A
(en)
|
2008-12-09 |
2013-01-25 |
Pfizer Vaccines Llc |
IgE CH3 PEPTIDE VACCINE
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
NZ594029A
(en)
|
2009-01-12 |
2014-01-31 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
RU2011140508A
(ru)
|
2009-03-06 |
2013-04-20 |
Новартис Аг |
Антигены хламидии
|
CN109248313B
(zh)
|
2009-04-14 |
2023-01-17 |
葛兰素史密丝克莱恩生物有限公司 |
用于免疫接种以抵御金黄色葡萄球菌的组合物
|
KR101450958B1
(ko)
|
2009-04-30 |
2014-10-15 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
폐렴구균 백신 및 그의 용도
|
EP2442826B1
(en)
|
2009-06-15 |
2015-07-08 |
National University of Singapore |
Influenza vaccine, composition, and methods of use
|
JP2012532600A
(ja)
|
2009-07-07 |
2012-12-20 |
ノバルティス アーゲー |
保存された大腸菌免疫原
|
PT2464658E
(pt)
|
2009-07-16 |
2015-01-14 |
Novartis Ag |
Imunogénios de escherichia coli desintoxicados
|
NZ618391A
(en)
|
2009-07-30 |
2015-07-31 |
Pfizer Vaccines Llc |
Antigenic tau peptides and uses thereof
|
EP2470204B1
(en)
|
2009-08-27 |
2015-12-16 |
GlaxoSmithKline Biologicals SA |
Hybrid polypeptides including meningococcal fhbp sequences
|
KR101660578B1
(ko)
|
2009-09-03 |
2016-09-27 |
화이자 백신스 엘엘씨 |
Pcsk9 백신
|
SI2475384T1
(sl)
|
2009-09-10 |
2016-12-30 |
Merial, Inc. |
Nove formulacije cepiva, ki obsegajo adjuvante, vsebujoče saponin
|
KR20120081587A
(ko)
|
2009-09-10 |
2012-07-19 |
노파르티스 아게 |
기도 질병에 대한 조합 백신
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
CA2779798C
(en)
|
2009-09-30 |
2019-03-19 |
Novartis Ag |
Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
WO2011039631A2
(en)
|
2009-09-30 |
2011-04-07 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
BR112012010531A2
(pt)
|
2009-10-27 |
2019-09-24 |
Novartis Ag |
"polipeptídeos de modificação meningocócica fhbp"
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011077309A2
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Vaccines Llc |
Vaccine compositions
|
EP2519265B1
(en)
|
2009-12-30 |
2018-11-14 |
GlaxoSmithKline Biologicals SA |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2552942B1
(en)
|
2010-03-30 |
2017-12-27 |
Children's Hospital & Research Center at Oakland |
Factor h binding proteins (fhbp) with altered properties and methods of use thereof
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
US9744228B2
(en)
|
2010-04-07 |
2017-08-29 |
Norvartis Ag |
Method for generating a parvovirus B19 virus-like particle
|
WO2011154863A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
EP2575868A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
US20130171185A1
(en)
|
2010-07-06 |
2013-07-04 |
Ethan Settembre |
Norovirus derived immunogenic compositions and methods
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
CN103282375B
(zh)
|
2010-12-02 |
2017-01-11 |
比奥诺尔免疫有限公司 |
肽支架设计
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
MX346475B
(es)
|
2011-01-06 |
2017-03-22 |
Bionor Immuno As |
Peptidos inmunogenicos monomericos y multimericos.
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
US10030052B2
(en)
|
2011-07-25 |
2018-07-24 |
Glaxosmithkline Biologicals Sa |
Parvovirus Vp1 unique region polypeptides and compositions thereof
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2755994A2
(en)
|
2011-09-14 |
2014-07-23 |
Novartis AG |
Escherichia coli vaccine combination
|
US9358284B2
(en)
|
2011-09-14 |
2016-06-07 |
Glaxosmithkline Biologicals Sa |
Methods for making saccharide-protein glycoconjugates
|
ES2704069T3
(es)
|
2011-12-08 |
2019-03-14 |
Glaxosmithkline Biologicals Sa |
Vacuna basada en toxinas de Clostridium difficile
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
MX2014010011A
(es)
|
2012-02-24 |
2014-09-08 |
Novartis Ag |
Proteinas y composiciones de pilus.
|
BR112014026812A8
(pt)
|
2012-04-26 |
2022-10-04 |
Novartis Ag |
Antígenos e combinações de antígenos
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP3563865A3
(en)
|
2012-05-04 |
2019-12-04 |
Pfizer Inc |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
SG11201407440WA
(en)
|
2012-05-22 |
2014-12-30 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
MX2014014683A
(es)
|
2012-06-06 |
2015-02-24 |
Bionor Immuno As |
Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
|
CA2882382A1
(en)
|
2012-09-18 |
2014-03-27 |
Novartis Ag |
Outer membrane vesicles
|
EA201590427A1
(ru)
|
2012-10-02 |
2015-09-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Нелинейные сахаридные конъюгаты
|
RU2015106791A
(ru)
|
2012-10-03 |
2016-11-20 |
Глэксосмитиклайн Байолоджикалз Са |
Иммуногенные композиции
|
AU2013351182C1
(en)
|
2012-11-30 |
2018-11-08 |
Glaxosmithkline Biologicals Sa |
Pseudomonas antigens and antigen combinations
|
CA2909586C
(en)
|
2013-05-15 |
2021-08-31 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
AU2015208821B2
(en)
|
2014-01-21 |
2017-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
CA3212723A1
(en)
|
2014-07-23 |
2016-01-28 |
Peter T. Beernink |
Factor h binding protein variants and methods of use thereof
|
FI3244917T3
(fi)
|
2015-01-15 |
2023-05-25 |
Pfizer |
Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
|
US10576131B2
(en)
|
2015-06-03 |
2020-03-03 |
Affiris Ag |
IL-23-p19 vaccines
|
WO2017005851A1
(en)
|
2015-07-07 |
2017-01-12 |
Affiris Ag |
Vaccines for the treatment and prevention of ige mediated diseases
|
TWI756893B
(zh)
|
2015-07-21 |
2022-03-01 |
美商輝瑞股份有限公司 |
包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
|
CA3005524C
(en)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
CA2954892A1
(en)
|
2016-01-19 |
2017-07-19 |
Pfizer Inc. |
Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
|
DK3570879T3
(da)
|
2017-01-20 |
2022-04-11 |
Pfizer |
Immunogene sammensætninger til anvendelse i pneumokokvacciner
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
CN112912097A
(zh)
|
2018-08-23 |
2021-06-04 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性蛋白和组合物
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2022512345A
(ja)
|
2018-12-12 |
2022-02-03 |
ファイザー・インク |
免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
JP2022528158A
(ja)
|
2019-04-10 |
2022-06-08 |
ファイザー・インク |
コンジュゲート化莢膜糖抗原を含む免疫原性組成物、それを含むキットおよびその使用
|
IL292494A
(en)
|
2019-11-01 |
2022-06-01 |
Pfizer |
Preparations of Escherichia coli and their methods
|
NL2027383B1
(en)
|
2020-01-24 |
2022-04-06 |
Aim Immunotech Inc |
Methods, compositions, and vaccines for treating a virus infection
|
US20230109142A1
(en)
|
2020-02-14 |
2023-04-06 |
Immunor As |
Corona virus vaccine
|
AU2021224078B2
(en)
|
2020-02-21 |
2024-01-18 |
Pfizer Inc. |
Purification of saccharides
|
EP4107170A2
(en)
|
2020-02-23 |
2022-12-28 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
TW202227467A
(zh)
|
2020-10-27 |
2022-07-16 |
美商輝瑞大藥廠 |
大腸桿菌組合物及其方法
|
KR20230097160A
(ko)
|
2020-11-04 |
2023-06-30 |
화이자 인코포레이티드 |
폐렴구균 백신에 사용하기 위한 면역원성 조성물
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
MX2023009728A
(es)
|
2021-02-19 |
2023-08-30 |
Sanofi Pasteur Inc |
Vacuna recombinante meningococica b.
|
TW202306969A
(zh)
|
2021-05-28 |
2023-02-16 |
美商輝瑞大藥廠 |
包含結合之莢膜醣抗原的免疫原組合物及其用途
|
PE20240090A1
(es)
|
2021-05-28 |
2024-01-16 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
|
CA3237496A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|